Dual Improvements in Dermatological Symptoms and Psychological Well-Being of Psoriasis Patients After Treatment with a Single Dose of Secukinumab: Three Case Reports

Abstract

Psoriasis is a chronic inflammatory skin condition that significantly impacts the physical and psychological well-being of affected individuals. It is characterized by well-demarcated, erythematous plaques with a white scaly surface. Beyond its dermatological manifestations, psoriasis is associated with systemic comorbidities, including arthritis, metabolic syndrome, cardiovascular diseases, and notably, psychological disorders such as depression and anxiety. We report a case series of patients suffering from moderate to severe psoriasis with concurrent mild to moderate depression. Patients administered with a single dose of 300 mg secukinumab, an interleukin-17 antagonist, showed significant improvements in psoriasis symptoms, quality of life, and depression levels within an 8-week period. This dual benefit underscores the importance of an integrated approach to managing patients with psoriasis, addressing both dermatological and psychological aspects.